Atorvastatin reduced major cardiovascular events by 30% among 9,971 adults aged 70 and older who had no known cardiovascular disease, diabetes or dementia, according to a large randomized NEJM study published Saturday. Over a median 5.9 years, 6.0% of participants assigned to atorvastatin experienced cardiovascular death, a nonfatal heart attack, stroke or coronary revascularization, compared with 8.3% of those given placebo. The hazard ratio was 0.70, with a 95% confidence interval of 0.61 to 0.82, a result unlikely to be explained by chance.

The same trial did not show that the drug extended life free from dementia or persistent physical disability, its other primary endpoint. That composite outcome occurred in 12.8% of the atorvastatin group and 13.6% of the placebo group, a difference that was not statistically significant. The paired findings give clinicians something unusually useful: direct evidence that a familiar medicine can prevent important vascular events in comparatively healthy older adults, alongside a clear boundary on what the trial demonstrated.

The STAtins in Reducing Events in the Elderly trial, known as STAREE, was presented at the European Society of Cardiology Congress in Munich on August 29. An ESC report said the double-blind study assigned participants equally to 40 milligrams of atorvastatin daily or an identical placebo. Their mean age was 74.7 years, and 52% were women. The result addresses one of preventive cardiology’s most persistent evidence gaps: whether to start statins after the age range that dominates earlier trials and risk calculators.

Why Older Adults Needed Their Own Trial

Statins lower low-density lipoprotein cholesterol by inhibiting an enzyme the liver uses to make cholesterol. Lower circulating LDL reduces the accumulation of cholesterol-rich plaque in arteries and the likelihood that a plaque will rupture and trigger a heart attack or ischemic stroke. That mechanism does not stop at a particular birthday, but the clinical balance changes with age because competing illnesses, medication burden, frailty and remaining life expectancy can all affect whether a preventive treatment produces a meaningful net benefit.

Earlier randomized evidence established statins as a cornerstone of prevention, yet relatively few trial participants were older than 75 and free of established vascular disease. A 2019 individual-participant Lancet analysis pooled 186,854 people in 28 trials, including 14,483 older than 75. It found vascular risk fell across age groups, but the evidence was thinner for people over 75 receiving treatment solely to prevent a first event. That distinction matters because benefits are clearest after a heart attack or stroke, when baseline risk is already high.

STAREE was designed to answer the primary-prevention question in people recruited through Australian general practices. Its published trial protocol deliberately paired the conventional cardiovascular endpoint with disability-free survival, reflecting what many older adults value: not only avoiding a heart attack, but remaining alive, cognitively intact and physically independent. Participants had to be living independently and could not already have a clinical indication that made statin treatment necessary.

A Large Relative Benefit With a More Modest Absolute Gain

The 30% figure is a relative reduction. The absolute difference between the groups was 2.3 percentage points over nearly six years, which translates to roughly one major cardiovascular event prevented for every 44 people treated during that period, using the reported event rates. Independent coverage calculated a somewhat lower number needed to treat using time-to-event methods. Either way, the result is clinically meaningful because heart attacks, strokes and coronary procedures can produce hospitalization, rehabilitation needs and lasting disability even when they are not fatal.

But the absence of a significant improvement in disability-free survival prevents the trial from being summarized as a general longevity benefit. The broader endpoint occurred in 637 atorvastatin recipients and 676 placebo recipients. An ACC summary noted the investigators’ explanation that about 80% of deaths in the trial were from noncardiovascular causes. Preventing a subset of vascular events may therefore be insufficient to move a composite dominated by the many other causes of death, dementia and physical decline in later life.

The null result also does not prove atorvastatin has no effect on any component of healthy aging. A composite can conceal different patterns among death, dementia and disability, and the confidence interval for the overall endpoint remained compatible with a modest benefit or a small disadvantage. What the trial establishes is narrower: it found a robust reduction in its prespecified cardiovascular composite, but not enough evidence that this translated into longer survival without dementia or persistent disability over the observed period.

Safety Findings Require Individual Interpretation

Serious adverse events were uncommon and identical in aggregate, affecting 2.7% of each group. Muscle-related, liver or biliary, and diabetes-related events were more frequent with atorvastatin, however, reinforcing the need to separate overall serious-event rates from specific drug-associated harms. The trial’s randomized, placebo-controlled design strengthens those comparisons because expectations and underlying health differences should have been distributed similarly between the groups.

The findings are reassuring on cognitive safety at the population level: dementia contributed to the disability-free survival endpoint, and the groups did not differ significantly on that composite. They do not mean every older adult will tolerate atorvastatin or that symptoms should be dismissed. Drug interactions, liver disease, muscle symptoms, frailty and the practical cost of adding another daily medicine remain relevant, particularly for people already taking several prescriptions.

Generalizability is another constraint. Participants were overwhelmingly White and healthy enough to live independently, so the results may not transfer perfectly to racially diverse populations, nursing-home residents, people with major frailty or those with several life-limiting illnesses. Adherence also weakened during prolonged follow-up, as it often does in prevention trials. Those limitations do not erase the randomized comparison, but they make a universal recommendation less defensible than a risk-based conversation.

Guidelines Now Have New Evidence to Weigh

U.S. guidance has reflected the uncertainty STAREE was built to resolve. The USPSTF has said evidence is insufficient to determine the balance of benefits and harms from initiating a statin for primary prevention at age 76 or older. Its recommendations are firmer for adults 40 to 75 who have risk factors and a sufficiently high estimated 10-year risk. STAREE supplies randomized evidence beyond that boundary, though its Australian population and exclusion criteria mean guideline panels will still need to judge how broadly to apply it.

The 2026 American College of Cardiology and American Heart Association guideline already says LDL-lowering therapy can be considered after age 75 alongside lifestyle measures. It also emphasizes individualized risk estimation and clinician-patient discussion rather than age alone. STAREE strengthens the evidence behind considering treatment, but it does not convert consideration into an automatic prescription for every healthy septuagenarian.

Baseline risk determines absolute benefit. Older age raises cardiovascular risk, but cholesterol, blood pressure, smoking, kidney function, family history and evidence of arterial plaque can move an individual’s probability substantially. U.S. CDC data show diagnosed heart disease rises sharply with age, yet STAREE focused on people without known disease. A person with very low LDL and limited life expectancy may gain little, while someone with several untreated risk factors and years of independent life ahead could gain more than the trial average.

What the Next Evidence Should Resolve

A large U.S. study should provide an important comparison. PREVENTABLE is following adults 75 and older through about 100 health systems to test whether atorvastatin helps prevent dementia, persistent disability and cardiovascular disease. Its pragmatic design, broad health-system network and American population may show whether STAREE’s cardiovascular benefit holds in a more diverse care environment and whether a different follow-up structure changes the healthy-aging result.

Guideline committees will also need component-level results, subgroup analyses and longer follow-up. The central questions include whether benefits differ above age 75, by sex, baseline LDL, frailty or coronary calcium, and whether the excess specific adverse events concentrate in identifiable patients. Subgroup results must be treated cautiously because a trial can lose statistical power quickly when divided into many smaller groups, but they can help identify hypotheses for clinical decisions and future studies.

For now, STAREE changes the evidence more than it simplifies the decision. In independently living adults over 70 without known cardiovascular disease, diabetes or dementia, 40 milligrams of atorvastatin reduced first major cardiovascular events over almost six years, with no aggregate increase in serious adverse events. It did not measurably extend disability-free survival. That combination supports a more informed prevention discussion, while leaving the final choice dependent on each patient’s vascular risk, competing health burdens, treatment preferences and tolerance for another long-term medicine.